Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FHTX 
Foghorn Therapeutics Inc (FHTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/27/2025: FHTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.58% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 202.98M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 145722 | Beta 3.13 | 52 Weeks Range 3.29 - 10.25 | Updated Date 04/1/2025 |
52 Weeks Range 3.29 - 10.25 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.285 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -840.51% |
Management Effectiveness
Return on Assets (TTM) -22% | Return on Equity (TTM) -470.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2241022 | Price to Sales(TTM) 8.98 |
Enterprise Value -2241022 | Price to Sales(TTM) 8.98 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 55612200 | Shares Floating 25845788 |
Shares Outstanding 55612200 | Shares Floating 25845788 | ||
Percent Insiders 18.94 | Percent Institutions 72.61 |
Analyst Ratings
Rating 4.43 | Target Price 12 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Foghorn Therapeutics Inc
Company Overview
History and Background
Foghorn Therapeutics Inc. was founded in 2016 and focuses on discovering and developing medicines targeting the chromatin regulatory system. It aims to address a broad spectrum of diseases, including cancer.
Core Business Areas
- Gene Traffic Controlu00ae Platform: This platform is used to discover and develop a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
- Oncology Programs: Development of therapies for cancer indications based on chromatin regulatory targets.
Leadership and Structure
The leadership team includes the CEO, Adrian Gottschalk, and other key executives in research, development, and operations. The organizational structure is typical of a biotechnology company, with functional departments supporting research, clinical development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- FOG-001: A selective BRD9 degrader. Currently in clinical trials for certain cancers. Market share data is not yet available as it is still in development. Competitors include companies developing similar targeted therapies, such as Arvinas and Cullinan Oncology.
- FOG-002: A CBP1/p300 inhibitor in preclinical stages. Market share data is unavailable at this stage. Competitors include companies working on epigenetic inhibitors, like Constellation Pharmaceuticals (acquired by MorphoSys).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. The field of chromatin regulation is relatively new and promising for cancer therapeutics.
Positioning
Foghorn Therapeutics is positioned as a leader in chromatin regulatory therapies, leveraging its Gene Traffic Control platform to discover and develop novel drugs. Their competitive advantage lies in their platform and expertise in this specific area.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is substantial, estimated to be hundreds of billions of dollars globally. Foghorn is positioned to capture a portion of this market with its novel approach if approved.
Upturn SWOT Analysis
Strengths
- Proprietary Gene Traffic Control platform
- Experienced management team
- Strong intellectual property portfolio
- Focus on a novel and promising therapeutic area
Weaknesses
- Early stage of development (high clinical risk)
- High cash burn rate
- Dependence on research and development success
- Limited revenue stream
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Advancements in understanding of chromatin regulation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- ARVN
- CULL
Competitive Landscape
Foghorn Therapeutics competes with other biotechnology companies developing novel cancer therapies. Its advantages include its focus on chromatin regulation and its proprietary platform. Disadvantages include being a smaller company with limited resources compared to larger pharmaceutical firms. Market share is currently negligible as they have no approved product for sales.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's growth is primarily reflected in its R&D progress and advancement of its pipeline assets through clinical trials.
Future Projections: Analyst projections are not provided. Refer to financial analysts' reports for estimated growth projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for FOG-001 and FOG-002, securing partnerships, and presenting data at scientific conferences.
Summary
Foghorn Therapeutics is a biotechnology company pioneering therapies targeting the chromatin regulatory system, presenting a promising yet high-risk investment. Its Gene Traffic Control platform and focus on novel mechanisms offer potential, while clinical trial outcomes and financial stability remain critical. They need to secure partnerships to get more money to help their product and be aware of clinical trials.
Similar Companies
- ARVN
- CULL
Sources and Disclaimers
Data Sources:
- Foghorn Therapeutics Inc. website
- SEC filings
- Industry reports
- Company Presentations
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Market share percentages are estimates and subject to change. Investing in biotechnology companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Foghorn Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-10-23 | President, CEO & Director Mr. Adrian H. B. Gottschalk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://foghorntx.com |
Full time employees 112 | Website https://foghorntx.com | ||
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.